Drug intelligence / Profile preview

IMB-1002

Development stage: Preclinical
Lead developer: IMIDomics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

IMB-1002 is a bispecific antibody drug candidate developed by Imidomics for the treatment of immune-mediated inflammatory diseases. It is currently in preclinical development, with primary indications including ulcerative colitis and systemic lupus erythematosus. The drug is designed to target disease pathways relevant to immune system, digestive system, skin, and musculoskeletal disorders. Its precise mechanism of action has not been publicly disclosed as of the latest updates[1][4].

Beyond the preview

Go deeper on IMB-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB-1002.

Explore the full profile